22nd Century Group (NASDAQ:XXII – Get Rating) posted its earnings results on Thursday. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01, MarketWatch Earnings reports. 22nd Century Group had a negative return on equity of 38.82% and a negative net margin of 105.37%. During the same quarter last year, the company earned ($0.03) EPS.
Shares of NASDAQ:XXII opened at $1.76 on Friday. The company has a 50-day simple moving average of $2.16. 22nd Century Group has a 52-week low of $1.74 and a 52-week high of $5.25.
Several research firms have weighed in on XXII. Roth Capital began coverage on 22nd Century Group in a report on Tuesday, March 8th. They set a “buy” rating and a $6.00 target price on the stock. Zacks Investment Research downgraded 22nd Century Group from a “buy” rating to a “hold” rating in a research report on Thursday.
22nd Century Group Company Profile (Get Rating)
22nd Century Group, Inc, an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies.
- Get a free copy of the StockNews.com research report on 22nd Century Group (XXII)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.